138 related articles for article (PubMed ID: 15002121)
1. Prolactinomas.
Couldwell WT; Weiss MH; Laws ER
N Engl J Med; 2004 Mar; 350(10):1054-7; author reply 1054-7. PubMed ID: 15002121
[No Abstract] [Full Text] [Related]
2. Prolactinomas.
Friedman TC
N Engl J Med; 2004 Mar; 350(10):1054-7; author reply 1054-7. PubMed ID: 14999121
[No Abstract] [Full Text] [Related]
3. Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Bilbao I; Egaña N; García C; Olaizola I
Endocrinol Diabetes Nutr; 2017 Dec; 64(10):564-566. PubMed ID: 29137963
[No Abstract] [Full Text] [Related]
4. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
5. Pituitary gland: can prolactinomas be cured medically?
Molitch ME
Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
Miki N
Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
[No Abstract] [Full Text] [Related]
7. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
[TBL] [Abstract][Full Text] [Related]
8. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
Werner S
Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
[No Abstract] [Full Text] [Related]
9. Demographic characteristics, presentations and treatment outcome of patients with prolactinoma.
Malik S; Hussain SZ; Basit R; Idress N; Habib A; Zamant M; Islam N
J Ayub Med Coll Abbottabad; 2014; 26(3):269-74. PubMed ID: 25671924
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
11. Long-term management of prolactinomas--use of long-acting dopamine agonists.
Cook DM
Rev Endocr Metab Disord; 2005 Jan; 6(1):15-21. PubMed ID: 15711910
[No Abstract] [Full Text] [Related]
12. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
13. Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline.
Verhelst JA
J Clin Endocrinol Metab; 1999 Dec; 84(12):4747. PubMed ID: 10599748
[No Abstract] [Full Text] [Related]
14. [Capacities of chemotherapy for pituitary tumors].
Vaks VV; Dedov II
Zh Vopr Neirokhir Im N N Burdenko; 2005; (2):30-6; discussion 36-7. PubMed ID: 16078633
[No Abstract] [Full Text] [Related]
15. Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia.
van Uum SH; van Alfen N; Wesseling P; van Lindert E; Pieters GF; Nooijen P; Hermus AR
J Neurol Neurosurg Psychiatry; 2004 Oct; 75(10):1489-91. PubMed ID: 15377706
[TBL] [Abstract][Full Text] [Related]
16. Effect of cabergoline on metabolism in prolactinomas.
Auriemma RS; Granieri L; Galdiero M; Simeoli C; Perone Y; Vitale P; Pivonello C; Negri M; Mannarino T; Giordano C; Gasperi M; Colao A; Pivonello R
Neuroendocrinology; 2013; 98(4):299-310. PubMed ID: 24355865
[TBL] [Abstract][Full Text] [Related]
17. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
18. Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline.
Delgrange E; Donckier JE
J Clin Endocrinol Metab; 1999 Dec; 84(12):4746-7. PubMed ID: 10599747
[No Abstract] [Full Text] [Related]
19. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
Colao A; Lombardi G
J Clin Endocrinol Metab; 1997 Aug; 82(8):2756. PubMed ID: 9253368
[No Abstract] [Full Text] [Related]
20. Prolactin serum concentrations after electroconvulsive therapy in a depressed patient with cabergoline-treated prolactinoma: implications for treatment.
Feneberg E; Gahr M; Baumgarten E; Connemann B; Merger S; Özpeynirci Y; Schönfeldt-Lecuona C
J ECT; 2015 Jun; 31(2):e28-9. PubMed ID: 26000778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
